CHM 0.00% 1.4¢ chimeric therapeutics limited

Our CHM 0201 Vactosertib trial is recruiting...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,200 Posts.
    lightbulb Created with Sketch. 3885
    Our CHM 0201 Vactosertib trial is recruiting again:
    https://clinicaltrials.gov/study/NCT05400122?tab=table

    And our new COO will be presenting at the Bio International Convention on in San Diego next month (5th June):
    https://convention.bio.org/sessions/chimeric-therapeutics

    Maybe we will get an update on CHM 2101 (CDH17) by then which is "scheduled to open in mid-2024."

    As to the upcoming dilution, well, we all knew that money will be needed and after the last two rounds in short succession, the company had to go for a different approach. While we always hope for a partnership or licensing deal when it comes to funding, early stage biotech "surprises" you 9 times out of 10 with a Cap Raise or any other shape or form of dilution. But that 1 time out of 10, that's what we are all hoping for here given our current MC compared to other biotech companies in this space. Even the dilution won't stop this from taking off if our clinical data holds up.
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.